Novartis Plugs Gaps in Pharma Pipeline
Executive Summary
Novartis hopes that Vertex Pharmaceuticals' structure-based drug design will deliver at least eight product candidates that target protein kinases into its development pipeline in the next six years. That's the goal for their new alliance, under which Novartis is providing Vertex $200 million in research funding, another $200 million as an interest-free loan (which will be forgiven to the extent that the monies drawn cover development of products Novartis accepts for development), milestones, and royalties. In fact, Vertex could receive as much as $600 million prior to commercialization--more than the industry benchmark for target discovery deals, the $425 million Bayer/Millennium collaboration. But unlike that deal, in which technology exchange was a vital component, this is an outsourcing by Novartis of its R&D in the area--accounting for about a third of its current R&D spending on external collaborations.
You may also be interested in...
Novartis Out, Merck In, a Win for Vertex's Aurora Kinase Program
Earlier this year, Vertex and Novartis reworked their 2000 deal covering R&D of drugs against kinases. The shift has already proved consequential. Vertex had yet to present a compound to Novartis: the original arrangement called for Vertex to conduct all R&D through early clinical proof of concept and the most advanced molecule, VX-680, was just at IND filing. With Novartis unwilling to decide on VX-680 before seeing clinical data, as part of the renegotiation Vertex was able to regain control of the compound then license it to Merck. For that compound, at least, Vertex got from Merck what it couldn't get from Novartis: significant value and an earlier handoff of an asset.
Novartis Out, Merck In, a Win for Vertex's Aurora Kinase Program
Earlier this year, Vertex and Novartis reworked their 2000 deal covering R&D of drugs against kinases. The shift has already proved consequential. Vertex had yet to present a compound to Novartis: the original arrangement called for Vertex to conduct all R&D through early clinical proof of concept and the most advanced molecule, VX-680, was just at IND filing. With Novartis unwilling to decide on VX-680 before seeing clinical data, as part of the renegotiation Vertex was able to regain control of the compound then license it to Merck. For that compound, at least, Vertex got from Merck what it couldn't get from Novartis: significant value and an earlier handoff of an asset.
Aventis Antes Up in Antibodies
Aventis SA's oncology franchise is anchored by the blockbuster Taxotere. Sales of the drug comprise more than 8% of Aventis's core pharma business, and are currently growing more than 25% worldwide and in the US. Yet until recently, the firm had few other products with which to leverage its commercial infrastructure in oncology. It is therefore teaming up with ImmunoGen Inc. to create antibody-based oncology therapeutics using drug targets provided by both companies.